当前位置: 首页 >> 检索结果
521. Intragastric maldistribution of a liquid meal in patients with reflux oesophagitis assessed by three dimensional ultrasonography.
作者: S Tefera.;O H Gilja.;E Olafsdottir.;T Hausken.;J G Hatlebakk.;A Berstad.
来源: Gut. 2002年50卷2期153-8页
Our aim was to study intragastric volume and distribution of a liquid meal in patients with reflux oesophagitis using three dimensional ultrasonography.
522. Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomised pilot study.
作者: R Moreau.;T Asselah.;B Condat.;C de Kerguenec.;F Pessione.;B Bernard.;T Poynard.;M Binn.;J D Grangé.;D Valla.;D Lebrec.
来源: Gut. 2002年50卷1期90-4页
Patients with cirrhosis and tense ascites treated by paracentesis alone have a decrease in effective arterial blood volume after ascites removal. Although intravenous albumin is effective in preventing paracentesis induced decreased arterial blood volume, its clinical use is controversial. As paracentesis induces arteriolar vasodilation which plays a role in the development of decreased effective arterial blood volume, administration of a vasoconstrictor (terlipressin) could prevent circulatory alterations due to paracentesis.
523. Protective effect of faecal occult blood test screening for colorectal cancer: worse prognosis for screening refusers.
Screening for colorectal cancer (CRC) by faecal occult blood testing (FOBT) decreases CRC mortality by 15-33%. Compliance remains an obstacle to maximising the benefit of FOBT screening. We tested the hypothesis that individuals offered FOBT screening but refused would have an increased incidence and worse prognosis for CRC compared with those tested and with controls.
524. A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds.
Three randomised trials have demonstrated reduction in mortality from colorectal cancer (CRC) by repeated screening with faecal occult blood tests, including the trial presented here, which is the only one still in progress.
525. Control of transient lower oesophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in patients with gastro-oesophageal reflux disease.
Transient lower oesophageal sphincter relaxations (TLOSRs) are the major cause of gastro-oesophageal reflux in normal subjects and in most patients with reflux disease. The gamma aminobutyric acid (GABA) receptor type B agonist, baclofen, is a potent inhibitor of TLOSRs in normal subjects. The aim of this study was to investigate the effect of baclofen on TLOSRs and postprandial gastro-oesophageal reflux in patients with reflux disease.
526. Effects of cisapride on gall bladder emptying, intestinal transit, and serum deoxycholate: a prospective, randomised, double blind, placebo controlled trial.
作者: M J Veysey.;P Malcolm.;A I Mallet.;P J Jenkins.;G M Besser.;G M Murphy.;R H Dowling.
来源: Gut. 2001年49卷6期828-34页
Octreotide inhibits gall bladder emptying and prolongs intestinal transit. This leads to increases in the proportion of deoxycholic acid in, and cholesterol saturation of, gall bladder bile, factors that contribute to the pathogenesis of octreotide induced gall stones.
527. A randomised controlled trial of high versus low long chain triglyceride whole protein feed in active Crohn's disease.
作者: K Leiper.;J Woolner.;M M Mullan.;T Parker.;M van der Vliet.;S Fear.;J M Rhodes.;J O Hunter.
来源: Gut. 2001年49卷6期790-4页
Polymeric feeds have shown variable efficacy in active Crohn's disease (CD) with remission rates from 36% to 82%. Meta-analyses of elemental, peptide, and whole protein feeds have shown a strong negative correlation between remission rate in CD and the long chain triglyceride (LCT) content of the feed. We performed a randomised controlled double blind trial in patients with active CD comparing two single whole protein feeds with LCT supplying 5% or 30% of the total energy.
528. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses.
作者: W Kruis.;S Schreiber.;D Theuer.;J W Brandes.;E Schütz.;S Howaldt.;B Krakamp.;J Hämling.;H Mönnikes.;I Koop.;M Stolte.;D Pallant.;U Ewald.
来源: Gut. 2001年49卷6期783-9页
Balsalazide is a new 5-aminosalicylic acid (5-ASA) containing prodrug. Its efficacy in comparison with standard mesalazine therapy and the optimum dose for maintaining remission of ulcerative colitis are still unclear.
529. Can endoscopic papillary balloon dilation really preserve sphincter of Oddi function?
Endoscopic papillary balloon dilation (EPBD) is assumed to preserve sphincter of Oddi function because it causes little trauma to the papilla. However, few studies have addressed this issue specifically. In this study, we investigated whether EPBD can preserve sphincter function, and evaluated whether or not such preservation has clinical significance.
530. Olsalazine is not superior to placebo in maintaining remission of inactive Crohn's colitis and ileocolitis: a double blind, parallel, randomised, multicentre study.
作者: N Mahmud.;M A Kamm.;J L Dupas.;D P Jewell.;C A O'Morain.;D G Weir.;D Kelleher.
来源: Gut. 2001年49卷4期552-6页
The benefit of 5-aminosalicylic acid therapy for maintenance of remission in Crohn's disease is controversial. The primary aim of this study was to evaluate the prophylactic properties of olsalazine in comparison with placebo for maintenance of remission in quiescent Crohn's colitis and/or ileocolitis.
531. Reducing community dyspepsia drug costs: a controlled trial.
Dyspepsia drug costs account for nearly 0.5% of the National Health Service budget. We hypothesised that improved management of dyspepsia would lead to reduced drug costs.
532. The cost of long term therapy for gastro-oesophageal reflux disease: a randomised trial comparing omeprazole and open antireflux surgery.
作者: H E Myrvold.;L Lundell.;P Miettinen.;S A Pedersen.;B Liedman.;J Hatlebakk.;R Julkunen.;K Levander.;M Lamm.;C Mattson.;J Carlsson.;N O Ståhlhammar.; .
来源: Gut. 2001年49卷4期488-94页
To comprehensively assess the relative merits of medical and surgical therapy for gastro-oesophageal reflux disease (GORD), health economic aspects have to be incorporated. We have studied the direct and indirect costs of medical and surgical therapy within the framework of a prospective randomised multicentre trial.
533. Effects of a motilin receptor agonist (ABT-229) on upper gastrointestinal symptoms in type 1 diabetes mellitus: a randomised, double blind, placebo controlled trial.
作者: N J Talley.;M Verlinden.;D J Geenen.;R B Hogan.;D Riff.;R W McCallum.;R J Mack.
来源: Gut. 2001年49卷3期395-401页
Erythromycin, a motilin agonist, is a potent prokinetic. ABT-229 is a specific motilin agonist that dose dependently accelerates gastric emptying. Dyspepsia and gastroparesis are common problems in type 1 diabetes mellitus. We aimed to evaluate the efficacy of ABT-229 in symptomatic diabetic patients with and without delayed gastric emptying.
534. Drug treatments in upper gastrointestinal bleeding: value of endoscopic findings as surrogate end points.
Pharmacotherapy for upper gastrointestinal bleeding has been difficult to evaluate because clinical end points are infrequent and affected by other factors.
535. Risks, costs, and compliance limit colorectal adenoma surveillance: lessons from a randomised trial.
作者: J N Lund.;J H Scholefield.;M J Grainge.;S J Smith.;C Mangham.;N C Armitage.;M H Robinson.;R F Logan.
来源: Gut. 2001年49卷1期91-6页
In the USA and many other countries, endoscopic surveillance of colorectal adenoma patients is now widely practised. However, the optimal frequency and mode of such surveillance are not yet established. The aim of this trial was to compare surveillance at one, two, or five year intervals using either flexible sigmoidoscopy or colonoscopy.
536. Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease.
作者: J F Colombel.;P Rutgeerts.;H Malchow.;M Jacyna.;O H Nielsen.;J Rask-Madsen.;S Van Deventer.;A Ferguson.;P Desreumaux.;A Forbes.;K Geboes.;L Melani.;M Cohard.
来源: Gut. 2001年49卷1期42-6页
New lesions of Crohn's disease occur early after ileal or ileocolonic resection and ileocolonic anastomosis. We performed a double blind controlled trial to evaluate the safety and tolerance of recombinant human interleukin 10 (IL-10; Tenovil) in subjects operated on for Crohn's disease. We also assessed the effect of Tenovil in preventing endoscopic recurrence 12 weeks after surgery.
537. Regulation of gastric function by endogenous gastrin releasing peptide in humans: studies with a specific gastrin releasing peptide receptor antagonist.
作者: P Hildebrand.;F S Lehmann.;S Ketterer.;A D Christ.;T Stingelin.;J Beltinger.;A H Gibbons.;D H Coy.;J Calam.;F Larsen.;C Beglinger.
来源: Gut. 2001年49卷1期23-8页
The main goal of our study was to characterise the activity of BIM26226 as a peripheral gastrin releasing peptide (GRP) receptor antagonist in healthy human subjects and to determine if endogenous GRP is a physiological regulator of gastric acid secretion and gastrin release.
538. Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis.
作者: A Gramenzi.;P Andreone.;S Fiorino.;C Cammà.;M Giunta.;D Magalotti.;C Cursaro.;C Calabrese.;V Arienti.;C Rossi.;G Di Febo.;M Zoli.;A Craxì.;G Gasbarrini.;M Bernardi.
来源: Gut. 2001年48卷6期843-8页
The role of interferon treatment on the natural history of hepatitis C virus related cirrhosis is under debate.
539. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial.
作者: G Pomier-Layrargues.;J P Villeneuve.;M Deschênes.;B Bui.;P Perreault.;D Fenyves.;B Willems.;D Marleau.;M Bilodeau.;M Lafortune.;M P Dufresne.
来源: Gut. 2001年48卷3期390-6页
The transjugular intrahepatic portosystemic shunt (TIPS) is a new therapeutic modality for variceal bleeding. In this study we compared the two year survival and rebleeding rates in cirrhotic patients treated by either variceal band ligation or TIPS for variceal bleeding.
540. Hypermethylation of the promoter region of the E-cadherin gene (CDH1) in sporadic and ulcerative colitis associated colorectal cancer.
作者: J M Wheeler.;H C Kim.;J A Efstathiou.;M Ilyas.;N J Mortensen.;W F Bodmer.
来源: Gut. 2001年48卷3期367-71页
Ulcerative colitis associated colorectal cancer (UCACRC) has several distinctive clinicopathological and genetic features which differ from sporadic colorectal cancer (SCRC). Hypermethylation of the E-cadherin gene (CDH1) has not been described previously in colorectal cancer.
|